Fox Trial Finder

New Study Shows the Incidence of Parkinson's Disease in the U.S. is 50% Higher than Previous Estimates

Retrieved on: 
星期四, 十二月 15, 2022
Perelman School of Medicine at the University of Pennsylvania, The Michael J. Fox Foundation, Social Security, Comparative Toxicogenomics Database, MD, Doctor of Philosophy, Parkinson's disease, Neurodegeneration, Facial expression, Fox Trial Finder, Prevalence, Patient, Tremor, University, Parkinson's Foundation, Research, Death, Alzheimer's disease, Disease, Rest, Incidence, Government, History, Social, Growth, Ageing, Clinical trial, Volunteering, MJFF, Depression, Anxiety, PD, ICES, Medicare, Organization, Palladium, Pharmaceutical industry, Neurology

NEW YORK and MIAMI, Dec. 15, 2022 /PRNewswire/ -- A new study reveals that the annual incidence of Parkinson's disease (PD) among older adults is 50% higher than current estimates of 60,000 diagnoses annually. The peer-reviewed study, which measured new cases of PD, or the number of people diagnosed with PD per year, was published in the scientific journal npj Parkinson's Disease on Dec. 15, 2022.   

Key Points: 
  • PD incidence estimates are higher in males as compared to females at all ages.
  • PD incidence rates are higher in certain geographic regions: the "Rust Belt," Southern California, Southeastern Texas, Central Pennsylvania and Florida.
  • "These updated estimates of incidence are necessary for understanding disease risk, planning health care delivery, and addressing care disparities," said James Beck, PhD, co-author of the study and chief scientific officer at the Parkinson's Foundation.
  • Prior PD incidence rates, based on smaller studies, were estimated to be in the 40,000 60,000 range per year.

The Michael J. Fox Foundation for Parkinson's Research Honors J. Timothy Greenamyre, MD, PhD, with Robert A. Pritzker Prize for Leadership in Parkinson's Research

Retrieved on: 
星期二, 十一月 1, 2022
Goal, Awareness, Pritzker family, Mitochondrion, The Michael J. Fox Foundation, Marmon Group, Biomedical sciences, Doctor of Philosophy, Clinical trial, Research, Emory University, MJFF, Parkinson's disease, Family, Neurodegeneration, Disease, Pesticide, Leadership, Pittsburgh Institute of Mortuary Science, Cell, Rotenone, View, Engineering, Government, Illinois Institute of Technology, Volunteering, Neurology, Professor, University, Foundation, PD, Pritzker Architecture Prize, Moshe Sherer, IIT, Genetics, Biomedical Research, Patient, Paraquat, Multimedia, Drug development, Environment, Science, Fox Trial Finder, Pharmaceutical industry, MD, Facebook

This science has and will continue to resonate through the field," said MJFF's Executive Vice President, Research Strategy Todd Sherer, PhD.

Key Points: 
  • This science has and will continue to resonate through the field," said MJFF's Executive Vice President, Research Strategy Todd Sherer, PhD.
  • The Robert A. Pritzker Prize for Leadership in Parkinson's Research, awarded annually by MJFF since 2011, was established by Karen Pritzker, daughter of Robert A. Pritzker, and her late husband, investor Michael Vlock.
  • "The Robert A. Pritzker Prize for Leadership in Parkinson's Research has recognized, annually, some of the most amazing Parkinson's scientists around the world.
  • The Robert A. Pritzker Prize for Leadership in Parkinson's Research is named in honor of the late Robert A. Pritzker, a renowned industrialist, entrepreneur and philanthropist.

Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease

Retrieved on: 
星期四, 十月 27, 2022
Eye, Therapy, Company, The Michael J. Fox Foundation, CNS, University, PD, MD, Trial of the century, Diagnosis, Disease, Disease management, Data monitoring committee, Research, Patient, Fox Trial Finder, Retina, GLOBE, University of California, San Diego Performance-Based Skills Assessment, Safety, Tremor, SAN, Knowledge, MJFF, Parkinson, Biomarker, Pharmaceutical industry, Medical imaging

This grant will support the first-in-human study of a retinal tracer targeting alpha-synuclein (ASYN) in a Prospective Randomized Open, Blinded Endpoint (PROBE) clinical study which is currently enrolling participants.

Key Points: 
  • This grant will support the first-in-human study of a retinal tracer targeting alpha-synuclein (ASYN) in a Prospective Randomized Open, Blinded Endpoint (PROBE) clinical study which is currently enrolling participants.
  • Additional information regarding the Phase 1/2a trial (NCT05542576) may be found at Fox Trial Finder.
  • We are honored to receive this third grant award which marks a longstanding collaboration with The Michael J.
  • Fox Foundation, said Dr. Stella Sarraf, chief executive officer and founder of Amydis.

Michael J. Fox Foundation for Parkinson's Research and Parkinson Alliance Announce Transition of the Parkinson's Unity Walk

Retrieved on: 
星期四, 九月 8, 2022
Patient, CO, Research, MJFF, Friends, Government, Awareness, Disease, Policy, Volunteering, The Michael J. Fox Foundation, LinkedIn, Parkinson's disease, Quality of life, Organization, Foundation, Goal, NEW, Parkinson, PD, Instagram, Unity, Twitter, Clinical trial, Industry, Fox Trial Finder, Public policy, Pharmaceutical industry, Facebook

Parkinson's Unity Walk annual fundraiser that gathers thousands from the PD community in Central Walk to transition from Parkinson Alliance to Michael J.

Key Points: 
  • Parkinson's Unity Walk annual fundraiser that gathers thousands from the PD community in Central Walk to transition from Parkinson Alliance to Michael J.
  • Fox Foundation for Parkinson's Research (MJFF) and The Parkinson Alliance announced today that the Parkinson's Unity Walk a fundraising event held each April in New York City's Central Park will be hosted by MJFF starting in 2023.
  • To commemorate the event's transition, Martin Tuchman, Chairman of The Parkinson Alliance, and Michael J.
  • The Parkinson Alliance stands as the umbrella organization for the Parkinson's Unity Walk, Team Parkinson, and other fundraising events held around the country.

ZyVersa Therapeutics and University of Miami Awarded a Grant from The Michael J. Fox Foundation to Determine if Inhibition of Microglial Inflammasome Activation with IC 100 Blocks Neuroinflammation Driving Parkinson's Disease Pathology

Retrieved on: 
星期三, 七月 27, 2022
Goal, Inflammation, University, View, Phenotype, Multiple sclerosis, Kidney, Awareness, Center, Neurosurgery, Paralysis, ASC, Physiology, Traumatic brain injury, Twitter, Foundation, The Michael J. Fox Foundation, Parkinson's disease, Research, Government, FSGS, PFF, Associate, CNS, NIH Intramural Research Program, Therapy, Focal segmental glomerulosclerosis, Multimedia, DRS, Volunteering, Clinical trial, Fox Trial Finder, Ageing, Inflammasome, Cognitive neuroscience, Kidney disease, Miami, Patient, LinkedIn, Department, Stroke, Faculty, Microbiology, Alport syndrome, Invention, MJFF, Miami Project to Cure Paralysis, Pharmaceutical industry, Medicine, Immunology, Biophysics, Facebook

WESTON, Fla., July 27, 2022 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (ZyVersa), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is honored to receive a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to determine if IC 100 inhibition of inflammasomes and ASC specks blocks microglial-mediated inflammation in a PD model. The research will be conducted at the University of Miami Miller School of Medicine in the labs of IC 100 inventors, Drs. Robert W. Keane and Juan Pablo de Rivero Vaccari. Dr. Keane is Professor, Departments of Physiology and Biophysics, Neurological Surgery and Microbiology, Immunology, and The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine. Dr. de Rivero Vaccari is an Associate Professor in the Department of Neurological Surgery and The Miami Project to Cure Paralysis, and a Distinguished Faculty Member of the Center for Cognitive Neuroscience and Aging at the University of Miami Miller School of Medicine.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF) to determine if IC 100 inhibition of inflammasomes and ASC specks blocks microglial-mediated inflammation in a PD model.
  • The research will be conducted at the University of Miami Miller School of Medicine in the labs of IC 100 inventors, Drs.
  • Dr. Keane is Professor, Departments of Physiology and Biophysics, Neurological Surgery and Microbiology, Immunology, and The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine.
  • Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today.

The Michael J. Fox Foundation Remembers Visionary Philanthropist Mrs. Lily Safra

Retrieved on: 
星期五, 七月 22, 2022
Goal, Brain, Diagnosis, View, Education, The Michael J. Fox Foundation, Awareness, For Hope, Industry, Instagram, Twitter, Foundation, CEO, Culture, Parkinson's disease, Research, Genetics, Government, Partnership, Religion, Neurology, Board, Movement disorders, Multimedia, Volunteering, LEAPS, Organization, Leadership, Quality of life, Clinical trial, Fox Trial Finder, Genome-wide association study, Grief, Disease, Hope, Board of directors, Science, Memory, LinkedIn, Patient, NEW, Edmond, Program, Growth, MJFF, Lists of diseases, Medicine, Management, Pharmaceutical industry, PD, Facebook

Fox Foundation Board member Lily Safra, chairwoman of the Edmond J. Safra Foundation, passed away on July 9, 2022, at age 87

Key Points: 
  • Fox Foundation Board member Lily Safra, chairwoman of the Edmond J. Safra Foundation, passed away on July 9, 2022, at age 87
    Mrs. Safra's transformative generosity and leadership supported a wide range of The Michael J.
  • Fox Foundation for Parkinson's Research (MJFF) mourns the loss of visionary philanthropist and Foundation Board member Lily Safra , who passed away on Saturday, July 9, 2022 in Geneva, Switzerland.
  • As chairwoman of the Edmond J. Safra Foundation, Mrs. Safra provided transformative support to hundreds of organizations around the world in the name of her late husband, Edmond J. Safra.
  • Edmond J. Safra lived with Parkinson's disease (PD), and Mrs. Safra was deeply committed to finding a cure.

New Resource, "Better Brain Health -- A Guide to Caring for Your Magnificent Brain at Every Age," Provides Expert Advice on Boosting Brain Health and the Latest Research

Retrieved on: 
星期一, 六月 6, 2022
Dream, MJFF, Life, Neurological disorder, Goal, Parkinson, Time, The Michael J. Fox Foundation, Research, Cell, Anosmia, Parkinson's disease, LinkedIn, Child, Disease, Government, Awareness, Motivation, Volunteering, Multimedia, Rapid eye movement sleep behavior disorder, GBA, Brain, Patient, REM, Risk, Fox Trial Finder, Movement, Diagnosis, NEW, Twitter, MD, Clinical trial, Population, Medical community of ancient Rome, Alzheimer's disease, PD, Instagram, Foundation, View, USA Today, Ageing, Medical device, Medical imaging, Pharmaceutical industry, Facebook

Fox Foundation offers simple tips for boosting brain health, misconceptions about taking care of the brain and symptoms to monitor as you get older.

Key Points: 
  • Fox Foundation offers simple tips for boosting brain health, misconceptions about taking care of the brain and symptoms to monitor as you get older.
  • New resource also breaks down what it means to be at risk for brain disease, including definitions and personal profiles outlining the risk factors for Parkinson's.
  • Fox Foundation for Parkinson's Research (MJFF) launches a comprehensive and expert guide on protecting and preserving brain health and how to manage risk factors for brain disease, including Parkinson's disease (PD) and Alzheimer's disease.
  • Full of practical tips and expert advice, the free guide ( michaeljfox.org/brainhealth ) is aimed at educating anyone, at any age on boosting brain health.

FUJIFILM Cellular Dynamics Launches Parkinson’s Disease iCell DopaNeurons featuring LRRK2 and GBA Mutations

Retrieved on: 
星期二, 五月 24, 2022
Risk, Knowledge, Disease, Parkinson's disease, IPSC, Immortalised cell line, ICELL Network, Foundation, The Michael J. Fox Foundation, Patient, CDMO, Goal, LRRK2, Government, Global Burden of Disease Study, Health, Quality of life, Clinical trial, Association, Volunteering, Research, MJFF, Neuron, Awareness, Lancet, GBA, Genomics, Fujifilm, Fox Trial Finder, Therapy, PD, LinkedIn, Twitter, Prevalence, Drug discovery, Potency (pharmacology), GLOBE, Medical device, Pharmaceutical industry, Facebook, Innovation

MADISON, Wis., May 24, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cell (iPSC) products, announced today the launch of Parkinsons disease (PD) iCell DopaNeurons featuring LRRK2 (G2019S) and GBA (N370S) mutations , which are common PD risk-associated mutations.

Key Points: 
  • MADISON, Wis., May 24, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cell (iPSC) products, announced today the launch of Parkinsons disease (PD) iCell DopaNeurons featuring LRRK2 (G2019S) and GBA (N370S) mutations , which are common PD risk-associated mutations.
  • These PD iCell DopaNeurons were developed and manufactured by FUJIFILM Cellular Dynamics from iPSCs derived from PD participants in The Michael J.
  • FUJIFILM Cellular Dynamics expertise in differentiating and commercializing iPSC-derived cell products ensure a steady supply of iCell DopaNeurons LRRK2 (G2019S) and GBA (N370S) with consistent purity and relevant biological functionality to support sustained research in this field.
  • "The iPSCs generated from PD donors in MJFFs landmark PPMI study enabled us to develop much-needed cellular tools to advance the discovery and development of therapeutic treatments for Parkinsons disease, said Keith R. Olson, Ph.D., senior vice president of commercial operations, FUJIFILM Cellular Dynamics, Inc. We anticipate human stem cell-derived disease models, such as the iCell DopaNeurons for LRRK2 and GBA mutations, will become the standard for research and development of disease modifying therapeutics for Parkinsons disease patients.

WCG Selected as the Institutional Review Board of Record for The Michael J. Fox Foundation's Parkinson's Progression Markers Initiative

Retrieved on: 
星期二, 四月 26, 2022
Fox Trial Finder, IRB, IBC, Parkinson, Adult, Parkinson's disease, Research, The Michael J. Fox Foundation, WCG, Organization, LinkedIn, Review, Observational study, Volunteering, Industry, Multimedia, Partnership, Risk, Health, MJFF, Time, PD, Pharmaceutical industry

PRINCETON, N.J., April 26, 2022 /PRNewswire/ -- WCG today announced that The Michael J. Fox Foundation for Parkinson's Research (MJFF) has chosen it to be the institutional review board (IRB) of record for its Parkinson's Progression Markers Initiative (PPMI). PPMI is a longitudinal, observational study of participants with and without Parkinson's disease (PD). It is designed to identify biological markers and clinical changes associated with PD risk, onset, and progression. WCG IRB will review all PPMI research protocols and patient-facing communications, including patient recruitment, retention, and informed consent documents, and in-study instructions.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF) has chosen it to be the institutional review board (IRB) of record for its Parkinson's Progression Markers Initiative (PPMI).
  • It is designed to identify biological markers and clinical changes associated with PD risk, onset, and progression.
  • WCG IRB will review all PPMI research protocols and patient-facing communications, including patient recruitment, retention, and informed consent documents, and in-study instructions.
  • "We are extremely pleased to be partnering with WCG IRB on PPMI.

Nitrase Therapeutics Receives New Grant from The Michael J. Fox Foundation for Parkinson’s Research

Retrieved on: 
星期二, 四月 5, 2022
Therapy, LinkedIn, Fox Trial Finder, MJFF, Sofinnova, Clinical trial, Research, The Michael J. Fox Foundation, Conference, Cancer, Parkinson's disease, Government, Twitter, Goal, Investment, CA, GLOBE, Science, Foundation, Bristol Myers Squibb, Enzyme, Awareness, Patient, Disease, Volunteering, Pharmaceutical industry, Facebook

This grant was awarded to fund Nitrases continued research on a novel biomarker identified by Nitrase scientists that may help predict and diagnose Parkinsons disease.

Key Points: 
  • This grant was awarded to fund Nitrases continued research on a novel biomarker identified by Nitrase scientists that may help predict and diagnose Parkinsons disease.
  • This grant will fund additional research to further validate our findings as we seek to advance our science to patients in need.
  • Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J.
  • Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today.